inducing G 2 M arrest via p53, respectively (2) . This suggests that the integrity of the G 2 M cell cycle checkpoint may be important in the cytotoxicity of these agents and a site for intervention (3) . However, the multiple roles of p53 in regulating DNA-repair enzymes may be dependent on tumor type, and inherent-and acquired resistance to alkylating agents present major obstacles to successful treatment (4) .
Taxanes, mitotic inhibitors such as paclitaxel and docetaxel, used to treat a variety of malignant tumors, bind to the beta-tubulin subunits of microtubules. This induces a prolonged activation of the mitotic spindle checkpoint and mitotic arrest followed by mitotic slippage and induction of apoptosis (5) . Although considered cytotoxic, they are in fact cytostatic, with the arrest triggering cell death (6) . Taxanes also induce post-transcriptional acetylation and phosphorylation of p53. This increases intracellular p53, upregulating its target proteins p21 and Bax, inhibiting the cell cycle, and increasing apoptosis (5) . Unfortunately, cancer cells have weak spindle checkpoints and activate various pro-survival signals that lead to clinical resistance towards taxanes. In addition to resistance, taxanes, like DNA damaging agents, can also induce significant toxicity that may force treatment to become dose-limiting.
Increasing the concentration of DNA damaging and anti-mitotic agents or combining them to increase cytotoxicity generally enhances anti-tumor activity by activating multiple pathways (7) . For example, the cyclin D-CDK4/6-retinoblastoma protein (RB)-INK4 axis is universally disrupted, facilitating cancer cell proliferation prompting the targeting of CDK4/6 as non-toxic cell cycle inhibitors that maintain or increase efficacy while reducing the toxicity of either DNA damaging or anti-mitotic agents, alone or in combination, would clearly be welcome.
This suggests adding a CDK inhibitor to either a taxane or DNA-damaging agent would potentially decrease chemoresistance and increase efficacy (13) . However, because many CDK inhibitors are not selective, their use in concert with DNA-damaging agents can be complicated by a direct cell cycle arrest superimposed on the modulation of upstream components of the checkpoint and repair pathways (12) . Selective (14) and pan CDK inhibitors such as flavopiridol (15) , inhibit CDKs 1, 2, 4, 6 and 9 and induce cell cycle arrest at G 1 and G 2 through competitive inhibition of the ATP binding site, they also have a synergistic effect when combined with a DNA-damaging agent (11) or taxane (13) . This effect is complicated as direct inhibitors of CDK1 and CDK2 arrest the cell cycle in G 1 and G 2 , and may also inhibit the effect of proliferation-dependent agents (11) . The absence of pharmacodynamic end points for pan CDK inhibitors complicates confirmation of target inhibition, cytotoxicity is not limited to cycling cells, and appears independent from wild type or mutated p53 or Rb (16) .
Although exposure to a direct cell cycle inhibitor in combination with chemotherapeutic agents may increase chemosensitivity, evidence remains limited for enhanced activity of either a DNA damaging or anti-mitotic agent via a p53 regulated, CDK mediated pathway, independent of cell type or agent (17) .
p28, amino acids 50 to 77 of azurin, a cupredoxin secreted by Pseudomonas aeruginosa, is a non-toxic, amphipathic, anionic cell penetrating peptide that preferentially enters a wide variety of cancer cells (18, 19) . Upon entry, p28 binds to a mutational "cold spot" (20) within the DNA-binding domain (DBD) of p53 wt,mut where it blocks the binding of the E3 ligase Cop1, inducing a significant post-translational increase in the level and activity of wild type and mutant p53 (21) (22) (23) (24) (25) (26) . This increase in p53 wt,mut levels and activity upregulates p21 and p27, inducing a significant decrease in the intracellular level of the CDK2-cyclin A complex, essential proteins in Research.
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As a targeted, cytostatic therapy, p28 exhibits no significant adverse effects or toxicity (28) , exerts a prolonged block at G 2 M that leads to a significant apoptotic cell death in breast cancer cells (26) and prevents the carcinogen induced transformation of mouse mammary epithelial ducts (29) . Chemopreventive agents such as the antimitotic Vinca alkaloids that inhibit cellular proliferation also indirectly lead to apoptosis (6, 30) . As such p28 appears as a true cell cycle specific cytostatic agent that induces cytotoxicity indirectly via a p53 wt,mut mediated block at G 2 M (18, 26) .
In this study, we assessed the effects of p28 alone and in combination with IC 20 ,IC 50 concentrations of standard DNA damaging and anti-mitotic agents on the degree of cytotoxic effect in p53 wt,mut,null matched human prostate, breast cancer, glioblastoma, melanoma and neuroblastoma cell lines as a function of cell proliferation and p53 status. The results suggest that a sustained increase in p53 wt,mut in the presence of lower doses of either DNA damaging or anti-mitotic agents is a promising avenue to reduce the overall toxicity of chemotherapeutic agents while maximizing their efficacy.
Materials and Methods

Peptide Synthesis
p28 (Leu 50 -Asp 77 LSTAADMQGVVTDGMASGLDKDYLKPDD, 2914 Da) was synthesized by CS 6 PA), respectively. DTIC was obtained from APP Pharmaceuticals (Shaumburg, IL), dissolved in sterile water and diluted in MEM-E.
Human fibroblast, mammary MCF-10A cell line, and human cancer cell lines were obtained from American Type Culture Collection (authenticated using morphology, karyotyping, PCR and STR profile): prostate cancer, LNCaP (p53 wt , AR + ), DU145 (p53 mut , AR -), and PC-3 (p53 null , AR -); neuroblastoma, IMR-32 (p53 wt ) and SK-N-BE2 (p53 mut ); breast cancer, ZR-75 (p53 wt ) and MDA-MB-231 (p53 mut ); and glioblastoma, U87 (p53 wt ) and LN229 (p53 mut ). Human melanoma, Mel-29 (p53 wt ) and Mel-23 (p53 mut ), were established and characterized in our laboratory (authenticated using morphology and karyotyping) (31) . Cells were cultured in MEME supplemented with 10% heat-inactivated FBS (Atlanta Biological, Inc.) at 37°C in 5% CO 2 (18, 24, 25) .
Cell proliferation assays
Human cancer cells were cultured in MEM-E containing 2 mmol/L L-glutamine, 0.1 mmol/L essential amino acids supplemented with 10% heat inactivated fetal bovine serum (18) .
The doubling time of each cancer cell line (LNCaP, DU145, IMR-32, SK-N-BE2, Mel-29, Mel-23, U87, LN229, ZR-75, and MDA-MB-231) was determined as follows. Cells were seeded (triplicate) at 20,000 cells/well and cultured in MEM-E for 72 hr in the absence of cytotoxic agent or p28 changed daily as described previously (18, 26, 32, 33) . Proliferative rate was expressed as doubling time in hours. The doubling time of each cancer cell line was determined from semilogarithmic plots of initial cell number vs cell counts at 24, 48 and 72 hr. The relationship between doubling time and cytotoxic activity or difference in cytotoxic activity between agent(s) alone and in combination was analyzed by non-linear regression. Curves were fitted using GraphPad PRISM (version 5.0, La Jolla, CA) as a function of a non-linear one phase decay (maximum iterations: 1000, Cl: 95 %).
We initially determined the concentration of p28 (~100 µmol/L) that inhibited cell proliferation 20-50% (IC 20-50 ) across the p53 wt,mut cell lines (18, (24) (25) (26) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 26, 2016; DOI: 10.1158/0008-5472. CAN-15-2355 then established the IC 20-50 for cytotoxicity using a standard MTT assay (18) ( Table 1) . Each cell line was then exposed to a cytotoxic agent or p28 alone or p28 in combination with IC 20-50 dose of doxorubicin, DTIC, TMZ, paclitaxel or docetaxel to establish whether cytotoxicity was enhanced. Culture medium was replaced with fresh media containing p28 (quadruplicate), chemotherapeutic agent or an equal volume of medium (control; 8 replicates) daily for 72 hr.
Results were compared by analysis of variance ANOVA (Newman-Keuls Multiple Comparisons) (GraphPad InStat ver. 3.0). 
Xenograft tumor models
Results
Effect of p28 treatment on the growth of human cancer cells.
p28 inhibits the proliferation of a wide variety of p53 + human tumor cells in vitro (18, 26) and in vivo (34) . Figure 1 illustrates the inhibitory effect of 50 and 100 μmol/L p28 on the (25, 35) . The cytostatic effect on prostate cancer cell lines, LNCaP (p53 wt , AR + ) and DU145 (heterozygous p53 mut P223L,V274F, AR -), was time-(data not shown) and dosedependent, decreasing the proliferation of LNCaP and DU145 cell lines at 72 hr by 18% and 22% (p<0.001) at 100 μmol/L, respectively ( Fig. 1 ). p28 was not active against the p53 null cell line, PC3 (AR -), confirming our earlier report (24) . Exposure to 100 μmol/L p28 for 72hr decreased the proliferation of neuroblastoma IMR-32 (p53 wt ) and SK-N-BE2 (p53 mut C135F) cells ~35% from control as well as inhibiting the proliferation of human glioblastoma U87 (p53 wt ), LN229 (p53 mut K164E), breast cancer ZR-75 (p53 wt ), MDA-MB-231 (p53 mut R280K) and melanoma Mel-29 (p53 wt ) and Mel-23 (p53 mut internal deletion at 178-183) cell lines consistent with p28 inhibition of Mel-2 (p53 wt ) (18) (Fig. 1) . In contrast, exposure to 100 μmol/L p28 for 72hr did not decrease the proliferation (<5 %) of normal human cells; fibroblasts (control vs. p28, p p=0.77) and MCF-10A breast cells (p=0.48) as previously reported (24) . Collectively, the data demonstrate that p28 is an effective cytostatic agent against p53 wt and p53 mut cancer cell lines that do not harbor DNA contact mutations or a completely unfolded DNA binding domain (DBD) (24, 25) . These results are also consistent with suggestions that a potential gain-of-function associated with mutations in p53 is not universal phenomenon for p53 mutants (24, 25, 34) .
Similar results were observed in MDA-MB-231 and Mel-23 xenograft tumors ( Fig p28 enhances the activity of DNA damaging and anti-mitotic agents.
We determined the degree of cytotoxicity on the same set of cancer cell lines exposed to either p28 alone ( p28, p=0.67). It is noteworthy that, in general, the induction of cytotoxicity in response to p28 alone was inversely correlated with the doubling time of each cell line (pair), suggesting that the degree of cytotoxicity following exposure to p28 alone was related to the doubling time ( Fig. 4A ) (36) of the cell line exposed and duration of that exposure ( Fig. 3 ). This was not true of either DNA damaging or antimitotic agents at their IC 20 ,IC 50 concentrations ( Table 1 , Fig. 4B ), illustrating the difference between a true cytostatic and the cytostatic/cytotoxic agents currently in use as therapeutics (6) . It has been also suggested that it is difficult to discern whether the cytotoxic activity of standard chemotherapeutic agents is mediated via a different target (off target) (6) . Figure 4C Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 26, 2016; DOI: 10.1158/0008-5472. CAN-15-2355 vs. the agent alone. There was no apparent relationship (p=0.26) between the increase in cytotoxicity and p53 mutation status as they did not include DNA contact mutations or mutations that produce a complete unfolding of the p53 molecule ( Fig. 4D ).
Although all DNA-damaging and antimitotic agents induced a cytotoxic effect in all five p53 wt,mut,null cell lines treated ( Table 1 , Fig. 3 ), there were significant differences in the concentration of doxorubicin and p28 to effect a similar inhibitory response between p53 wt , p53 mut and p53 null cell lines of the same type ( Table 1 , Fig. 3A ). In contrast, the IC concentrations of DTIC and TMZ were similar across cell lines and p53 status. In general, concentrations of the antimitotic paclitaxel and docetaxel that achieved an IC 20 ,IC 50 were also cell line dependent, but not as dependent on p53 status as doxorubicin ( Table 1, Exposure of p53 wt LNCaP and p53 mut DU145 cells (but not p53 null PC3 cells) to doxorubicin increased p53, p21 and FoxM1, but not CDK2 levels relative to control. p28 alone also elevated p53 and p21 levels, but in contrast to doxorubicin decreased FoxM1 and CDK2 levels ( Fig. 5A ) and had no effect on p53 null PC3 cells. The increase in p53 in LNCaP and DU145 cells treated with p28 combined with doxorubicin was similar (LNCaP 242 % vs. DU145 223 %), as was the relative increase above doxorubicin alone. A similar increase in p21 levels was observed over doxorubicin, although the relative value compared to control was higher in DU145 cells ( Fig. 5A ), suggesting that either DNA damaging agents or p28 may be more effective in increasing p21 in ARprostate cancer cells. Doxorubicin also increased FoxM1 levels significantly over control in LNCaP and DU145 cells ( Fig. 5A ). FoxM1, an essential transcription factor for G 2 M progression in LNCaP and DU145 cells, is reportedly stabilized through the checkpoint pathway by DNA damage sensing kinases (e.g. ATM) and downstream signaling effectors including checkpoint kinase 2 in response to DNA damage (37) . An increase in FoxM1 suggests that the G 2 M transition is enhanced. As the expression level of CDK2 reportedly correlates with FoxM1 expression (38) , the increase in CDK2 in DU145 cells treated with doxorubicin was associated with the increase in FoxM1 (Fig. 5A) . In contrast to doxorubicin, the p28-induced increase in p53 reduced the levels of FoxM1 in LNCaP and DU145 cells ( Fig.   5A ) as previously reported (25) . This is not surprising as p53 negatively regulates FoxM1 expression independently of the checking pathway (39) . Exposure of LNCaP and DU145 cells to p28 alone or in combination with doxorubicin reduced CDK2 levels below that of control or doxorubicin alone, respectively, in parallel with FoxM1. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 26, 2016; DOI: 10.1158/0008-5472. CAN-15-2355 In contrast to doxorubicin, DTIC did not significantly increase the level of p53, p21 or FoxM1 in p53 wt U87 glioblastoma cells relative to control, but did reduce CDK2 levels. However, unlike p53 mut Mel-23 melanoma cells, ( Fig. 2E, F ; 3C) and p53 wt U87 glioblastoma (Fig. 3D ), DTIC did increase p53 mut and p21 significantly in p53 mut LN229 cells ( Fig. 5B ) without altering either FoxM1 or CDK2. p28 alone also increased the levels of p53 and p21 in p53 wt U87 and p53 mut LN229 cells while decreasing the levels of FoxM1 and CDK2 in both lines. Exposure to p28 in combination with DTIC increased the levels of p53 and p21 above that of either control or DTIC alone without altering the levels of FoxM1 and decreasing CDK2 in both cell lines, mirroring the increase in efficacy ( Fig. 3D ). A similar pattern was observed in the responses of p53, p21, FoxM1 and CDK2 for TMZ in U87 and LN229 cells. Addition of p28 produced a pattern of expression similar to that of DTIC that paralleled the activity of the combination in both lines. In sum, the increased activity of DNA-damaging agents ( Fig. 5A -C) in combination with p28 appeared to result from the activation of the p53/p21 axis, significantly reducing CDK2 levels relative to each agent alone and enhancing the cytotoxicity of lower concentrations of these agents.
Exposure of p53 wt LNCaP cells to the antimitotic paclitaxel increased the levels of p53 and p21, but did not alter FoxM1 or CDK2 (Fig. 5D ). The increase in p53 and p21 levels in p53 wt LNCaP cells treated with p28 in combination with paclitaxel was qualitatively similar to cells treated with paclitaxel alone (Fig. 5D ). Although the level of FoxM1 was not altered by p28 and paclitaxel in LNCaP cells, CDK2 was significantly reduced to levels below that observed with p28 alone. The paclitaxel-induced cytotoxic effect in p53 mut DU145 cells (Fig. 3D) , was accompanied by a decrease in p53 mut relative to control, while slightly increasing p21 and significantly elevating FoxM1 and CDK2 above control levels (Fig. 5D ). The increase in FoxM1 in p53 mut DU145 cells treated with paclitaxel alone (Fig. 5D ) reportedly occurs in response to the paclitaxel-induced decrease in p53, a paclitaxel-induced early activation of p53/p21 pathway (40) , or activation via a p53-independent pathway (41) . As p28 in combination with paclitaxel increased p53 and p21 while significantly decreasing FoxM1 and CDK2 levels below that observed with paclitaxel alone and control, it suggests the mutations in p53 in this cell line do not prevent p28 from enhancing the generalized cytotoxicity observed with paclitaxel alone (Fig.   2B ,3F,G) (5, 42) . The increased activity of paclitaxel in combination with p28, coupled with the increase in p53 and p21 and decrease in FoxM1 and CDK2 compared to that of paclitaxel alone, was likely due to the post-translational increase in p53 and p21 induced by p28 ( Fig. 5D ) that enhanced the cytotoxic activity of paclitaxel in this cell line.
Unlike paclitaxel, docetaxel, the taxane prescribed for advanced ARprostate cancer, increased p53 and FoxM1 without significantly altering either p21 or CDK2 levels in LNCaP cells ( Fig. 5E ). Here again, p28 in combination with docetaxel further increased the level of p53 and p21 while inhibiting FoxM1 and CDK2 levels. Docetaxel, unlike paclitaxel did not significantly alter either p53 or p21 levels in DU145 cells, but did increase FoxM1 while leaving CDK2
unchanged, suggesting subtle differences in the mechanism of action of these two taxanes.
However, p28 in combination with docetaxel increased p53 and p21 levels while significantly decreasing the expression of FoxM1 and CDK2 below that in docetaxel-treated and control DU145 cells (Fig. 5E ), a pattern similar to that observed with paclitaxel ( Fig. 5D ).
Chemotherapeutic agents do not alter the interaction of p28 with p53
Administration of cytotoxic drugs can have far-reaching secondary consequences that may contribute to overall cytotoxic activity. For example, doxorubicin in combination with a recombinant human interleukin-1α (IL-1), induces a significant synergistic antiproliferative effect in human melanoma cells by increasing IL-1 binding to the receptor on melanoma (43) .
Genotoxic drugs can also trigger multiple molecular events including activation of p53independent checkpoints partially protecting cancer cells during chemotherapy (44 can be avoided with agents targeted specifically at enhancing p53 activity. Treatment of tumor cells with doxorubicin causes phosphorylation and acetylation of p53, transcriptional upregulation of p21 and other target genes, and growth arrest (45) . These observations coupled with the ATP-dependent, nuclear pore-mediated transport of the doxorubicin-proteasome complex suggests the possibility that doxorubicin could directly or indirectly alter the affinity of p53 for p28. We explored this possibility with competitive pull-down assays of p28 binding to p53 in lysates from cells previously treated with either doxorubicin or paclitaxel. GST coupled to p28 (GST-p28) pulled down endogenous p53 from p53 wt LNCaP and p53 mut DU145 cells; GST alone did not (Fig. 6 ). The L 1 (aa 112-124) and S 7 -S 8 (aa 214-236) loops and T140, P142, Q144, W146, R282 and L289 of the p53DBD have been identified as potential sites for p28 binding (24) . Although DU145 is heterozygous for mutations in p53 (P223L, V274F), p28 pulled down p53 mut from DU145 more effectively than p53 wt in LNCaP (Fig. 6, lanes 2 and 6, top panel) . This confirms our earlier results showing that the heterozygous mutant p53 (P223L, V274F) had a higher affinity for p28 (-59 kJ/mol) than wt p53 (25) . Neither paclitaxel nor doxorubicin altered the interaction of p28 with p53 in LNCaP and DU145 cells ( Fig. 6 ). Although p28 in combination with paclitaxel and doxorubicin enhanced cytotoxicity effect in LNCaP and DU145 (Fig. 3) , the enhancement was not the result of an altered affinity between p28 and p53 ( Fig. 6 ).
Discussion
The majority of expressed p53 mutations reportedly exhibit gain-of-function properties actively promoting pro-survival signals and tumorigenesis, independent of the loss of wild-type p53 function (46) . Although gain-of-function effects are complex (46) , an apoptosis-resistance feature appears to be directly linked to high expression of mutant p53 (47) . Tumors that depend on an inactivated e.g. mutated, p53 for continued proliferation are inhibited if p53 is reactivated. to apoptosis, it affords the opportunity to combine restoration of p53 activity with lower doses of DNA damaging and anitmitotic therapy to further increase efficacy and reduce toxicity. This approach would appear to be most effective in high grade tumors with rapid doubling times, as an increase in overall effectiveness of multiple combinations of p28 with DNA damaging or antimitotic agents appears dependent on a rapid proliferative rate (Fig. 4) . DNA damaging agents induce apoptosis in cancer cells by activating p53 through the ATM pathway (48) .
Since suppression of at least certain types of mutant p53 renders cancer cells highly susceptible
Taxanes also induce p53 via post-transcriptional modifications that increase both its level and activity (5) . To date, strategies directed at activating p53 in tumors have largely focused on targeting wild-type p53 rather than the mutated p53 present in a significant percentage of most solid tumors. Fortunately, a significant percentage of these mutations are single point, missense mutations that allow the expression of a p53 mut that essentially remains functional (49) . This is in sharp contrast to other tumor suppressor proteins (e.g. the cyclin D-CDK4/6-retinoblastoma protein (RB)-INK4 and p16) that are generally inactivated by homozygous deletion, additional smaller deletions or promoter methylation that produce a truncated unstable protein or complete lack of expression. These observations also suggest that drugging p53 wt and a significant number of p53 mut tumors to induce p53-dependent suppression of cell growth is a viable option for treatment.
The post-translational increase in p53 levels and activity induced by a non-genotoxic p28 significantly increases the downstream CDK inhibitors p21 and p27 inhibiting CDK2 and the cell cycle at G 2 M (26) in virtually all p53 wt and p53 mut tumors devoid of DNA contact mutations or mutations that produce a complete unfolding of the p53 molecule (25, 26) . Neither the CDK4/6 pathway, p16 INK4A nor senescence is invoked (26). For example, p28 increased the level of p53 and p21 in p53 wt LNCaP and p53 mut DU145 prostate cancer and p53 wt U87 and p53 mut LN229 glioblastoma cells, but decreased the p53 negatively regulated FoxM1 and CDK2 proteins ( DU145 prostate cancer cells (Fig. 5A ). Since several DNA mismatch repair proteins (MLH1, PMS1 and PMS2) are inactivated in DU145 cells (50) , the level of FoxM1 in response to DNAdamage was higher than in LNCaP cells (Fig. 5A ). FoxM1 is also transcriptionally regulated by E2F1 which induces the accumulation of FoxM1 in response to DNA damage, suggesting that the DNA-damage response pathway also regulates FoxM1 independent of p53 (51) . CDK2 expression was not altered by doxorubicin alone in either cell line, but significantly reduced when combined with p28 reflecting the increase in levels of p53 and p21 above either agent alone (Fig. 5A) . The levels of CDK2 in cancer cells treated with DNA damaging agents paralleled those of FoxM1, as CDK2 expression transcriptionally correlates with FoxM1 expression, supporting a role for CDK2 during FoxM1-induced cell cycle progression (38) .
These data clearly suggest that the enhanced cytotoxicity with p28 and doxorubicin in combination in prostate cancer and neuroblastoma (Fig. 3A,B) is a direct result of a p28-induced increase in p53.
Expression of DNA repair proteins also plays a decisive role in protecting cells against the effect of alkylating agents. The DNA repair enzyme O 6 -alkylguanine DNA alkyltransferase (AT) repairs O 6 -methylguanine in DNA by transferring the methyl group to a cysteine acceptor site on the protein itself (52) . Expression of AT is reportedly mediated through p53 (52) , suggesting that induction of this DNA repair pathway in p53 wt U87 cells in response to DTIC or TMZ treatment fails to alter p53 levels (Fig. 5B,C) . However, p21 expression was increased following exposure of U87 cells to TMZ, but not DTIC, suggesting a difference in the mechanism of action of these two similar agents. This was not the case with either agent in p53 mut LN229 cells ( Fig. 5B,C essentially what we observed ( Fig. 3 D,E; Fig. 5B,C) . p28 alone increased p53 levels in U87 and LN229 cells (Fig. 5B,C) , in turn decreasing the level of FoxM1 in U87 and LN229 cells. As a cell cycle specific inhibitor at G 2 M, p28 exhibits anti-proliferative activity independent of DNA repair pathway. Since p28 in combination with DTIC or TMZ increases the levels of p53 and p21 in U87 and LN229 cells, it suggests that the increase in cytotoxicity induced by p28 in combination vs. the agent alone extends to a variety of DNA-damaging agents and may also be independent of cancer cell phenotype (Fig. 3A-E ; 5A-C).
The repeated, significant decrease in CDK2 in response to an increase in p53 and p21, irrespective of cancer cell type, is significant as CDKs are also involved in activation of DNA damage checkpoint signaling and the initiation of DNA repair. Primary resistance to DNA damaging agents is partly due to the activation of checkpoint and repair pathways (53) . The inhibition of CDKs may prevent the activation of DNA-damage-induced checkpoint and repair pathways. It has been suggested that CDK1 (cdc2) and CDK2 may be the most attractive family members of CDK to target in combination with DNA-damaging agents because abrogation of individual CDK1 and CDK2 activity results in defective DNA-damage-response pathways in several types of human cancer cells (12) . However, because many inhibitors of CDK inhibit multiple CDK family members that carry a similar ATP-binding site, their use in combination with DNA damaging agents is complicated by a cell cycle arrest that may be superimposed on the checkpoint and repair pathways.
Unlike competitive small molecule inhibitors of the ATP-binding pocket on CDKs, p28
specifically inhibits the cancer cell cycle at G 2 M by inducing the endogenous CDK inhibitors, p21 and p27. This leads to lower levels of CDK2 and cyclin A, and a higher level of phosphorylated CDK1 (Thr14/Thr15; inactive form) in a p53-dependent manner (24) (25) (26) . The minimal response of CDK1 following exposure to p28 is also accompanied by a significant increase in the level of cyclin B1, indicating p28 inhibits the cancer cell cycle at G 2 M (26), as degradation of these two Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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It is also likely that a p53/p21 mediated inhibition of CDK2 plays a significant role in the enhanced effect when p28 is used in combination with antimitotic agents such as paclitaxel (55) and docetaxel in p53-positive cell lines irrespective of p53 status (Fig. 3F-H) . The increase in activity in p53 wt LNCaP cells correlated with a paclitaxel or docetaxel induced increase in p53 and p21 and decrease in FoxM1 and CDK2. This was not the case for DU145 cells, particularly with paclitaxel which significantly decreased p53 levels (Fig. 5D, E) . This was reversed with the addition of p28 which increased p53 and p21 and significantly reduced FoxM1 and CDK2 levels when combined with either paclitaxel or docetaxel. Although the potential for taxane resistance exists when cancer cells are exposed to taxanes in combination with CDK2 inhibitors, addition of p28 to a taxane regimen would avoid such resistance since CDK2 activity appears unrelated to paclitaxel sensitivity (56). Moreover, as p28 increases the level of phosphorylated cdc2 (CDK1) leaving the level of cdc2 virtually unchanged (26), the cytotoxic activity of a taxane is enhanced, an obvious benefit.
What is also clear is that the increase in cytotoxic activity following exposure of cancer cells to p28 in combination with either a DNA damaging or antimitotic agent does not result from either class of agents increasing (or decreasing) the affinity of p53 for p28 ( Fig. 6 ). The DNAdamaging agent, doxorubicin reportedly induces significant acetylation of p53 C-terminal domain (CTD) (45, 57) . Although such post-translational modifications within the p53CTD induce conformational changes of the p53DBD (57), doxorubicin did not alter the p28:p53 interaction irrespective of p53 mutation status (Fig. 6 ). This suggests the multiple molecular events including activation of p53-independent checkpoints triggered by exposure to genotoxic drugs that partially protect cancer cells during chemotherapy can be mitigated with p28 which directly enhances p53 activity (44).
Research.
Author Manuscript Published OnlineFirst on February 26, 2016; DOI: 10.1158/0008-5472.CAN- In sum, p28 in combination with DNA-damaging and antimitotic agents, increased their cytotoxicity by activating p53 wt,mut which subsequently induced the endogenous CDK inhibitor p21. The increase in p21 significantly enhanced their cytotoxic activity, independent of cancer cell type. Our results demonstrate the potential therapeutic value in targeting the p53/p21/CDK2 pathway in combination with lower doses of chemotherapeutic agents to improve anticancer efficacy while reducing toxicity.
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